Brain MRI Scans and Memory Tests in Young People With Acute Leukemia

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children, teens and young adults aged 0 to 30 with acute leukemia. It uses a quick brain scan and a game-style memory test to look for brain changes during chemotherapy.

Age

0 to 30 years

Sex

All sexes can join.

Disease stage

Acute leukemia: acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), or myeloproliferative neoplasm/leukemia. Newly diagnosed people are included.

Earlier treatment

People more than 2 weeks into induction chemotherapy for acute leukemia cannot join.

Main reasons for not taking part

• More than 2 weeks into induction chemotherapy for acute leukemia
• Heart pacemaker or heart defibrillator
• Metal in the eye, or some types of metal in the body, such as certain surgical clips for aneurysms in the head
• Heart valve prostheses, electrodes or other implanted devices
• Any other reason an MRI scan cannot be done

The registry criteria, word for word

What the trial wants to find out

The survival of children, adolescents and young adults (AYA) with acute leukemia has improved dramatically over the last two decades. This success is a result of using multiple chemotherapy drugs in combination, with the inclusion of drugs that enter the brain and prevent leukemia cells from growing there. Studies in these cancer survivors have shown that the exposure to these chemotherapy drugs can lead to risks for impaired brain function, also referred to as neurocognitive side effects of chemotherapy. There is an opportunity to identify participants at risk for these side effects and to prevent their development. The purpose of this study is to incorporate a brain imaging tool known as Magnetic Resonance Fingerprinting (MRF) to look for brain matter changes in acute leukemia participants receiving chemotherapy. The MRF scan will be performed at diagnosis and repeated at multiple times during the entire therapy duration as well as at defined intervals after therapy is complete. Investigators would also do an electronic test of memory and brain function (cognitive function), which would be administered in a gaming format on iPads or a similar device. The goal will be to correlate results of MRF imaging with the tests of cognitive function. The benefits of this imaging technique include that it can be done quickly (in minutes), it is non-invasive, it is resistant to motion-artifacts and it can be easily repeated for comparison purposes. The advantages of the cognitive test include its short duration of 20 minutes and its gaming format making it friendly for children to use.

The group in the trial

• MRF +/-Neurocognitive TestingOther group

  Once the participants meeting the inclusion criteria are identified and formally consent to participate in the study, each participant will undergo a baseline MRF imaging exam along with the neurocognative testing, preferably prior to starting induction chemotherapy. The total treatment duration for an individual participant can vary anywhere between 6 months - 3 years depending on the type of acute leukemia, so investigator plans to obtain MRF scans every 6 months during the therapy as well as during the first year of the off -therapy period

  Treatment: MRF with neurocognative studies